Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Zeng, Zhen ^a   Shi, Feng ^a,b   Zhou, Lin ^a   Zhang, Min Na ^a   Chen, Yan ^a   Chang, Xiu Juan ^a   Lu, Yin Ying ^a   Bai, Wen Lin ^a   Qu, Jian Hui ^a   Wang, Chun Ping ^a   Wang, Hong ^a   Lou, Min ^a   Wang, Fu Sheng ^a   Lv, Ji Yun ^a   Yang, Yong Ping ^a  

^a BEIJING 302 HOSPITAL   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CRYOABLATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UPREGULATION; BLOOD; CRYOSURGERY; DISEASE COURSE; HEPATITIS B VIRUS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

HEPATITIS B VIRUS;

ADULT; AGED; ANTIGENS, CD274; CARCINOMA, HEPATOCELLULAR; CRYOSURGERY; DISEASE PROGRESSION; FEMALE; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; UP-REGULATION;

EID: 80052365815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023621     Document Type: Article

References (43)

1. Rilling WS, Drooz A, (2002) Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol 13: S259-263.
2. Lencioni R, Chen XP, Dagher L, Venook AP, (2010) Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15: 42-52.
3. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
4. Llovet JM, Bruix J, (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442.
5. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC, (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev pp. CD001199.
6. Sabel MS, (2009) Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Croyobiology 58: 1-11.
7. Zhou L, Fu JL, Lu YY, Fu BY, Wang CP, et al. (2010) Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol 45: 968-978.
8. Yantorno C, Soanes WA, Gonder MJ, Shulman S, (1967) Studies in cryo-immunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 12: 395-410.
9. Shulman S, Brandt EJ, Yantorno C, (1968) Studies in cryo-immunology. II. Tissue and species specificity of the autoantibody response and comparison with iso-immunization. Immunology 14: 149-158.
10. Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, et al. (2005) Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90: 97-104.
11. Sabel MS, Arora A, Su G, Chang AE, (2006) Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor. Cryobiology 53: 360-366.
12. Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, et al. (2007) Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95: 491-498.
13. Poston G, (2001) Cryosurgery for colorectal liver metastases. Hepatogastroenterol 48: 323-324.
14. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8: 765-772.
15. Ishida Y, Agata Y, Shibahara K, Honjo T, (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895.
16. Nishimura H, Honjo T, (2001) PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22: 265-268.
17. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, et al. (2004) Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 155: 172-182.
18. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, et al. (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56: 1173-1182.
19. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 104: 3360-3365.
20. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11: 2947-2953.
21. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, et al. (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-1257.
22. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, et al. (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979.
23. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896.
24. Llovet JM, Brú C, Bruix J, (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
25. Wang C, Lu Y, Chen Y, Feng Y, An L, et al. (2009) Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis 26: 839-848.
26. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, et al. (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111: 3220-3224.
27. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, et al. (2007) PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13: 1757-1761.
28. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198.
29. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, et al. (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206: 1327-1337.
30. Xie Z, Chen Y, Zhao S, Yang Z, Yao X, et al. (2009) Intrahepatic PD-1/PD-L1 Up-regulation Closely Correlates with Inflammation and Virus Replication in Patients with Chronic HBV Infection. Immunological Investigations 38: 624-638.
31. Peng G, Li S, Wu W, Tan X, Chen Y, et al. (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45: 963-970.
32. Campbell DE, Tustin NB, Riedel E, Tustin R 3rd, Taylor J, et al. (2009) Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes. Clin Vaccine Immunol 16: 1648-1653.
33. Chen J, Wu XJ, Wang GQ, (2008) Hepatoma cells up-regulate expression of programmed cell death-1 on T cells. World J Gastroenterol 14: 6853-6857.
34. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, et al. (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 182: 5240-5249.
35. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544.
36. Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, et al. (2009) Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137: 682-690.
37. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, et al. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89: 500-507.
38. Wang ZL, Liang P, Dong BW, Yu XL, Yu de J, (2008) Prognostic Factors and Recurrence of Small Hepatocellular Carcinoma after Hepatic Resection or Microwave Ablation:A Retrospective Study. J Gastrointest Surg 12: 327-337.
39. Poon RT, Lau C, Pang R, Ng KK, Yuen J, et al. (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14: 1835-1845.
40. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
41. Martin-Orozco N, Dong C, (2007) Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol 17: 288-298.
42. Hayakawa S, (2006) No cancer in cancers: evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. Med Hypotheses 66: 888-897.
43. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I, (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37: 508-516.